AYJK(SZ:002172)2023-03-23 16:00Business Transformation - The company reported a significant shift in focus towards the healthcare sector after divesting its non-core business, with full commitment to medical health operations as of May 7, 2022[18]. - The company has undergone a transformation from primarily producing viscose staple fiber to establishing a dual business model in chemical fibers and health industries since 2015[17]. - The company completed the asset transfer and announced the completion of the transaction on May 7, 2022, marking a full transition to the health industry[93]. - The company divested from its chemical fiber business to focus entirely on the healthcare sector, aligning with its strategic transformation[88]. Financial Performance - The company's operating revenue for 2022 was ¥2,021,311,317.17, a decrease of 33.27% compared to ¥3,028,918,811.03 in 2021[20]. - The net profit attributable to shareholders was -¥15,389,790.15 in 2022, showing an improvement of 98.52% from -¥1,038,913,881.13 in 2021[20]. - The total assets at the end of 2022 were ¥2,708,031,538.51, down 29.17% from ¥3,823,219,194.07 at the end of 2021[20]. - The company reported a basic and diluted earnings per share of -¥0.02 in 2022, an improvement of 98.51% from -¥1.34 in 2021[20]. - The company reported a loss of ¥22,202,585.29 from investment income, representing 2,302.57% of total profit[65]. Revenue Breakdown - Revenue from medical services increased by 6.18% to CNY 1,006,694,205.21, accounting for 49.80% of total revenue[51]. - Revenue from pharmaceutical logistics decreased by 2.88% to CNY 997,697,746.78, representing 49.36% of total revenue[51]. - The total revenue for Jiangsu Aoyang Health Industry Co., Ltd. in 2022 was 613.84 million RMB, showing a significant increase compared to the previous year[105]. - The company reported a total revenue of 688.6 million with a growth rate of 64.88% compared to the previous year[152]. Strategic Initiatives - The company aims to enhance its brand and expand specialty services, focusing on building a high-level research institute in oncology[47]. - The company is actively pursuing investment opportunities in the medical service industry to strengthen its competitive position in East China[47]. - The company aims to optimize assets and upgrade the health industry and brand, focusing on the integration of medical, health, and elderly care services[94]. - The company is focusing on expanding its market presence in the health industry through strategic procurement[152]. Market Trends - The healthcare industry in China has shown a compound annual growth rate (CAGR) of 10.58% in total health expenditure from 2012 to 2021, reaching ¥76,844.99 billion[32]. - The number of private hospitals in China increased from 9,786 in 2012 to 24,766 in 2021, representing a compound annual growth rate of 9.73%[38]. - The total number of hospitals in China grew from 23,170 in 2012 to 36,570 in 2021, with the proportion of private hospitals rising from 42.24% to 67.72%[38]. Governance and Compliance - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management, ensuring accountability[3]. - The company has engaged Lixin Certified Public Accountants for auditing, ensuring compliance and transparency in financial reporting[19]. - The company has maintained a stable governance structure, complying with relevant laws and regulations without any major issues[135]. Employee and Management Information - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 3.64 million[116]. - The total number of employees at the end of the reporting period was 2,274, with 1,499 being technical personnel, representing approximately 66% of the workforce[124]. - The company conducted various training programs throughout the year, covering management, chemical fiber professional skills, and medical professional skills[127]. Future Outlook - The company plans to expand its market presence by entering three new provinces in 2023, aiming for a 25% increase in market share[108]. - The company has set a performance guidance for 2023, targeting a revenue growth of 30% compared to 2022[108]. - Future guidance includes an expected EBITDA margin improvement of 3% as a result of strategic investments and operational efficiencies[154]. Legal Matters - The company is involved in a lawsuit with a claim amount of ¥4,011.05 million, which has been recognized as a liability[147]. - Another lawsuit involves a claim amount of ¥2,616.29 million, with the court proceedings already initiated[147]. - The company has settled a dispute involving a claim of ¥1,682.42 million, with the execution of the settlement completed[148]. Risk Management - The company has acknowledged potential risks related to national policies affecting the healthcare industry, urging investors to remain aware of investment risks[3]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[138]. - The company has not encountered any bankruptcy reorganization matters during the reporting period[146].